<?xml version="1.0" encoding="UTF-8"?>
<document id="29053833">
	<sentence id="s1" text="Brown-Vialetto-glycoprotein biosynthetic process Laere syndrome represents a phenotypic spectrum of motor, sensory, and cranial nerve neuropathy, often with ataxia, optic atrophy and respiratory problems leading to ventilator-dependence.">
		<entity id="s1.e1" charOffset="15-48"
			type="GO" text="glycoprotein biosynthetic process" ontology_id="GO_0009101"/>
		<entity id="s1.e2" charOffset="134-144"
			type="HP" text="neuropathy" ontology_id="HP_0009830"/>
		<entity id="s1.e3" charOffset="157-163"
			type="HP" text="ataxia" ontology_id="HP_0001251"/>
		<entity id="s1.e4" charOffset="165-178"
			type="HP" text="optic atrophy" ontology_id="HP_0000648"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p3" e1="s1.e1"
		    e2="s1.e4" pgr="false"/>
	</sentence>
	<sentence id="s2" text="By screening a large cohort of 132 patients with early-onset severe sensory, motor and cranial nerve neuropathy we confirmed the strong genetic link between riboflavin transporter mutations and Brown-Vialetto-glycoprotein biosynthetic process Laere syndrome, identifying 22 pathogenic mutations in SLC52A2 and riboflavin transport, 14 of which were novel.">
		<entity id="s2.e1" charOffset="101-111"
			type="HP" text="neuropathy" ontology_id="HP_0009830"/>
		<entity id="s2.e2" charOffset="209-242"
			type="GO" text="glycoprotein biosynthetic process" ontology_id="GO_0009101"/>
		<entity id="s2.e3" charOffset="310-330"
			type="GO" text="riboflavin transport" ontology_id="GO_0032218"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e3" pgr="true"/>
	</sentence>
	<sentence id="s3" text="Our findings expand the genetic, clinical and neuropathological features of Brown-Vialetto-glycoprotein biosynthetic process Laere syndrome, implicate mitochondrial dysfunction as a downstream consequence of riboflavin transporter gene defects, and validate riboflavin esters as a potential therapeutic strategy">
		<entity id="s3.e1" charOffset="91-124"
			type="GO" text="glycoprotein biosynthetic process" ontology_id="GO_0009101"/>
		<entity id="s3.e2" charOffset="151-176"
			type="HP" text="mitochondrial dysfunction" ontology_id="HP_0003287"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
</document>
